Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

lilly_entrance_web

Lilly’s LOXO-292 shrinks tumours in lung cancer trial

September 9, 2019 Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma

Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …
News
shutterstock

Age affects efficacy of immunotherapy treatments in breast cancer patients

September 9, 2019 Research and Development, Sales and Marketing Cancer, breast cancer, pharma

Recent clinical trial data has shown that immune checkpoints blockade (ICB) therapy, designed to unleash a patient’s immune system to …
News
trump-fda

Trump’s FDA: Is the US regulator being steered by the President?

September 9, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Trump, US, drug safety, pharma

FDA activity has fallen under Donald Trump, with the number of warning letters issued by the regulator dropping by a …
Feature
novartis_side_building

4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine

September 9, 2019 Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma

Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 6, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mylan, brexit

It’s Friday, meaning the weekend is within reach and it’s time for a rundown of the most popular articles on …
News
shutterstock_273326141

Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal

September 5, 2019 Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma

Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …
News
opdivo_1_1

BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme

September 5, 2019 Research and Development BMS, glioblastoma multiforme, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …
News
shutterstock_3

Cancer drugs have surged since the 80s to account for 1 in 4 FDA approvals, report reveals

September 5, 2019 Research and Development, Sales and Marketing Cancer, FDA, US, pharma

The number of cancer drug approvals in the US has surged over the last decade to account for over one …
News
ai_graphic

Key legal considerations in accelerating pharma using artificial intelligence

September 4, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, artificial intelligence, pharma

Charlotte Walker-Osborn, Partner and International Technology Sector Head and Nabil Asaad, Senior Associate, Intellectual Property Law Group – both from …
Feature
w3_banners6

FREE WEBINAR: Leveraging technology for optimal engagement

September 4, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Webinar, Within3, pharma

Join Pharmafocus and Within3 for a special webinar event on Thursday, 19 September, for a session exploring the changing trends …
News
merckwindow_web

Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma

September 4, 2019 Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma

The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …
News
shutterstock_212432119

Ardelyx’s tenapanor combo meets all key goals at Phase 3 in hyperphosphatemia patients on dialysis

September 4, 2019 Research and Development Ardelyx, pharma, tenapanor

Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at …
News

NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy

September 4, 2019 Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma

NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …
News
astrazeneca_plaque

AZ’s Tagrisso secures China approval in first-line advanced lung cancer

September 4, 2019 Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma

AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …
News
shutterstock_2

NICE issues new quality standard for cerebal palsy treatment

September 3, 2019 Manufacturing and Production, Research and Development

NICE has moved to publish a draft quality standard on the treatment of cerebral palsy (CP) in adults, it has …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026